Scientific background of Hurler syndrome
Hurler syndrome (severe MPS I, MPS I-H) is a lysosomal storage disorder caused by biallelic pathogenic variants in the IDUA gene, which encodes the enzyme alpha-L-iduronidase. Deficiency of this enzyme leads to progressive accumulation of the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate in lysosomes, triggering a cascade of cellular and tissue damage across multiple organ systems.
This page provides a more technical overview of the molecular genetics, biochemical pathways and organ level mechanisms that underlie Hurler syndrome, complementing the more patient facing pathophysiology content elsewhere on the site.
This page is written for readers with some scientific or clinical background. It does not replace clinical guidelines or personalised medical advice.
IDUA gene, alpha-L-iduronidase and severe MPS I
Hurler syndrome is the severe end of the MPS I spectrum and is caused by:
- Biallelic pathogenic variants in the IDUA gene, located on chromosome 4p16.3
- Resultant quantitative or qualitative deficiency of lysosomal alpha-L-iduronidase activity
Key points:
- IDUA encodes alpha-L-iduronidase, which catalyses the hydrolysis of terminal alpha-L-iduronic acid residues from the non-reducing ends of dermatan sulfate and heparan sulfate chains.
- Classic Hurler phenotype is usually associated with variants that lead to minimal or absent residual enzyme activity (for example nonsense, frameshift or severe missense variants).
- Attenuated phenotypes (Hurler-Scheie, Scheie) are often associated with missense variants that retain partial activity, although genotype phenotype correlations are not absolute.
Dermatan sulfate, heparan sulfate and lysosomal catabolism
In health:
- Proteoglycans are continuously turned over.
- Endocytosed or autophagocytosed proteoglycans are delivered to lysosomes.
- Sequential action of specific exoglycosidases and sulfatases removes sugars and sulfate groups from the non reducing end of GAG chains.
- Alpha-L-iduronidase acts relatively early in this sequence, removing terminal alpha-L-iduronic acid residues from dermatan sulfate and heparan sulfate.
In Hurler syndrome:
- Alpha-L-iduronidase activity is markedly reduced or absent.
- Partially degraded GAGs accumulate within lysosomes in multiple cell types.
- Secondary effects include enlargement and dysfunction of lysosomes, impaired autophagic flux, and downstream cellular stress.
From substrate accumulation to global cellular stress
GAG accumulation in lysosomes leads to a number of interconnected cellular changes:
Lysosomal distension and trafficking defects
Enlarged lysosomes distort cellular architecture and may interfere with normal trafficking of vesicles and organelles.
Lysosomal exocytosis may increase, contributing to elevated extracellular and urinary GAGs.
Disrupted autophagy
Impaired degradation of autophagosomes leads to accumulation of damaged mitochondria and proteins.
This contributes to oxidative stress and altered cellular metabolism.
Inflammatory and signaling changes
GAGs and secondary storage products can activate innate immune pathways (for example via microglia in the CNS and macrophages in peripheral tissues).
Abnormal signaling through growth factor and cytokine pathways contributes to tissue remodeling and fibrosis.
Apoptosis and impaired cell survival
Chronic lysosomal and oxidative stress can trigger apoptotic pathways in vulnerable cell populations.
Over time, these cellular level abnormalities translate into organ level structural and functional damage.
Brain storage, neuroinflammation and neurocognitive decline
CNS disease is a defining feature of Hurler syndrome:
- Heparan sulfate is particularly relevant to CNS pathology, given its abundance in brain ECM and cell surfaces.
- Accumulation of heparan sulfate and secondary metabolites occurs in neurons, astrocytes and microglia.
- Microglial activation and neuroinflammation are consistent findings in experimental models and human tissue.
Mechanistic features:
- Impaired neuronal lysosomal function and autophagy interfere with synaptic maintenance and neurite structure.
- Abnormal storage in white matter and perivascular spaces contributes to MRI changes such as ventriculomegaly and white matter signal abnormalities.
- Disrupted neurodevelopmental signaling and chronic neuroinflammation likely contribute to progressive cognitive and functional decline if untreated.
Clinical correlation:
- Without early HSCT, children with Hurler syndrome typically develop severe neurocognitive impairment and loss of developmental skills in early childhood.
- Even with timely HSCT, some patients exhibit residual or emerging neurocognitive and behavioral difficulties, reflecting incomplete CNS correction.
Cartilage, bone and the skeletal dysplasia of MPS I-H
The skeleton is highly dependent on normal GAG metabolism in cartilage and growth plates:
- Chondrocytes in growth plate and articular cartilage have heavy GAG turnover.
- Lysosomal storage in chondrocytes disrupts normal matrix production, mineralization and ossification.
- Resulting abnormalities include dysostosis multiplex, short stature and joint deformity.
Key mechanistic aspects:
- Disturbed endochondral ossification leads to characteristic vertebral changes (e.g. beaked vertebrae, kyphosis), hip dysplasia and long bone abnormalities.
- Articular cartilage storage and secondary inflammation contribute to joint stiffness, contractures and pain.
- Conventional HSCT and ERT have limited penetration into avascular cartilage and growth plate zones, so skeletal disease often progresses despite systemic treatment.
Clinically, this manifests as progressive kyphoscoliosis, genu valgum, hip subluxation, reduced range of movement and chronic musculoskeletal pain, often requiring complex orthopaedic interventions
Valve disease, myocardial changes and vascular involvement
Cardiac involvement is common and multifactorial:
- Valve pathology
- GAG storage in valvular interstitial cells and extracellular matrix leads to leaflet thickening and dysfunction.
- Progressive aortic and mitral regurgitation and/or stenosis are frequently observed.
- Myocardial and conduction system
- GAG accumulation and secondary fibrosis can affect myocardium and conduction tissue.
- Cardiomyopathy and rhythm disturbances may occur in some patients.
- Vascular changes
- Storage within arterial walls may contribute to thickening, luminal narrowing and altered compliance.
Although HSCT and ERT can stabilize or improve some aspects of cardiac disease, particularly when given early, residual or progressive valve disease is common and often necessitates surgical replacement in later childhood or adulthood.
From enzyme deficiency to clinical phenotype
You can summarise the scientific background in a simple conceptual pathway that can also be turned into a figure:
Genetic level
- Biallelic pathogenic IDUA variants
- Alpha-L-iduronidase deficiency
Biochemical level
- Impaired degradation of dermatan sulfate and heparan sulfate
- Lysosomal GAG accumulation in multiple cell types
Cellular level
- Lysosomal distension, impaired autophagy, mitochondrial dysfunction
- Inflammatory signaling, oxidative stress, altered ECM turnover
Tissue level
- CNS storage and neuroinflammation
- Skeletal dysplasia and joint disease
- Valve thickening, airway narrowing, organomegaly
Clinical level
- Neurocognitive decline, dysostosis multiplex, cardiopulmonary compromise
- Multisystem morbidity and reduced quality of life
Key points from the scientific background
- Hurler syndrome is caused by severe deficiency of alpha-L-iduronidase due to biallelic IDUA variants, leading to accumulation of dermatan sulfate and heparan sulfate.
- Lysosomal GAG storage triggers widespread cellular dysfunction, including impaired autophagy, mitochondrial stress and inflammatory signaling.
- CNS, skeletal, cardiac, respiratory, ocular and auditory systems are all affected, producing the characteristic multisystem phenotype.
- HSCT and ERT partially correct the underlying biochemical defect but have limited impact on brain, bone and cartilage, especially when damage is established.
- These mechanistic insights underpin current clinical management and guide research into more targeted, tissue specific and CNS active therapies.
What to read next
Causes and genetics
IDUA variants and inheritance patterns
Body systems
Organ by organ impact of Hurler syndrome
Treatments and care
HSCT, ERT and supportive care strategies
Pathophysiology (family facing)
Plain language explanation of disease mechanisms
Unmet need
Residual morbidity and quality of life after treatment
Research hub
Registries, trials and emerging therapies